Pdl Biopharma (PDLI) 3.38 $PDLI
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 21, 4:35PM CST
FIT: 12.86 (+0.39), MDR: 3.88 (+0.03), MIC: 63.98 (+1.47), SREV: 4.32 (+0.01), VECO: 18.96 (+0.27), HURN: 59.54 (+0.67), MHLD: 12.27 (-0.20), OKE: 26.36 (-0.24), SHO: 13.65 (+0.06), MRC: 13.74 (+0.34), ELGX: 9.20 (+0.36), ACC: 43.73 (-0.59), MSI: 70.95 (-0.30), PSIX: 10.97 (-0.03), ONDK: 8.00 (+0.31), VVC: 46.99 (+1.01), THC: 27.06 (-1.03), HLX: 4.55 (-0.17), ESRT: 16.21 (-0.07), PEB: 28.41 (-0.43), SGY: 2.56 (+0.10), ROG: 56.07 (+0.32), OKS: 30.79 (-0.36), CRZO: 26.44 (+0.89), SPN: 12.74 (-0.18), QTS: 45.19 (-0.41), TXRH: 42.82 (+0.59), QUAD: 12.79 (-0.11), IVR: 12.24 (+0.07), NDSN: 74.93 (+0.85), CJES: 1.73 (+0.10), RAIL: 16.24 (-0.10), DEPO: 15.44 (-0.09), PDLI: 3.38 (-0.04), DDS: 84.11 (-0.43), CHGG: 4.40 (-0.07), CHMT: 25.35 (+0.36), TMH: 45.43 (+0.24), LNT: 69.36 (+0.68), MMSI: 19.21 (+0.08), IPHS: 29.62 (+0.92), NLS: 18.25 (+1.36)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 9.04 (+0.22), XNCR: 11.54 (-0.23), PDLI: 3.38 (-0.04)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.71 (-0.01), CLVS: 21.58 (+0.10), RLYP: 13.87 (+0.04), PDLI: 3.38 (-0.04)
PDL BioPharma, Inc. Shares Just Fell Off a Cliff -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 02, 3:30PM CST
What: Shares of PDL BioPharma , a biotech company that focuses on purchasing and developing royalty-based patented assets, sank as much as 13% after the company outlined its new dividend policy. So what: According to PDL BioPharma's press...
PDLI: 3.38 (-0.04)
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
PDLI: 3.38 (-0.04)
PDL BioPharma Announces 2016 First Quarter Dividend
PR Newswire - Mon Feb 01, 3:02PM CST
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the first quarter of 2016. The dividend will be paid on March 11, 2016 to all stockholders who own shares of PDL on March 4, 2016, the record date for the first quarter dividend payment.
PDLI: 3.38 (-0.04)
3 High-Risk Dividend Stocks I'd Avoid
Andrés Cardenal, Tyler Crowe, and George Budwell, The Motley Fool - Motley Fool - Sat Jan 30, 8:20AM CST
Most investors love dividend stocks, and for good reasons. Statistical studies have proven time and again that investing in companies with strong dividends can be a powerful strategy to achieve superior returns from your portfolio over the long...
PM: 94.49 (+1.23), WMB: 19.15 (+1.06), ETE: 8.33 (+0.43), MO: 62.98 (+0.75), WPZ: 22.01 (-1.13), PDLI: 3.38 (-0.04)
Stock to Watch: PDL BioPharma Down 5.4% (PDLI)
Comtex SmarTrend(R) - Mon Jan 11, 12:48PM CST
PDL BioPharma (NASDAQ
DLI) is one of today's worst performing low-priced stocks, down 5.4% to $3.09 on 1.0x average daily volume. Thus far today, PDL BioPharma has traded 2.4 million shares, vs. average volume of 2.4 million shares per day. The stock has underperformed the Dow (-5.4% to the Dow's -0.4%) and underperformed the S&P 500 (-5.4% to the S&P's -0.8%) during today's trading.
PDLI: 3.38 (-0.04)
2 Cheap Stocks Not Worth Their (Incredibly Low) Price
Motley Fool Staff - Motley Fool - Tue Jan 05, 2:43PM CST
If you're thinking of investing in stocks under $5, even in mid- and large-cap companies, make sure you're getting a deal instead of low-value paper. As you might expect, a lot of cheap shares are cheap for a reason. In this clip of Industry...
MNKD: 1.17 (+0.07), PDLI: 3.38 (-0.04)
What Makes a Stock "Cheap"?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sat Jan 02, 10:19AM CST
If you're looking to stuff your portfolio with a few little cheap stocks this season, make sure you know how to choose between undervalued steals and junk about to crash and leave you with nothing. On this episode of Healthcare Industry Focus ,...
GILD: 87.21 (-0.62), PFE: 29.71 (-0.18), MYL: 44.78 (-0.95), MNKD: 1.17 (+0.07), PDLI: 3.38 (-0.04)
The Worst 3 Biotech Stocks for 2016
Brian Feroldi, The Motley Fool - Motley Fool - Wed Dec 30, 9:23AM CST
Image by Tax Credits via Flickr Creative Commons. Biotech investing isn't for the faint of heart. It takes more than a decade of research and development efforts costing an average of $2.6 billion to bring just a single drug to market. Even then,...
MNKD: 1.17 (+0.07), ARNA: 1.51 (-0.05), PDLI: 3.38 (-0.04)
5 Stocks We're Staying Away From in 2016
Brian Feroldi, Selena Maranjian, Sean Williams, Brian Stoffel, and Jason Hall, The Motley Fool - Motley Fool - Sun Dec 20, 7:11PM CST
Image by PeteLinforth via Pixabay. Investing in the stock market is one of the best wealth-building tools available to individual investors, as the returns provided from the market's best growth companies can be jaw dropping . Still, finding those...
PM: 94.49 (+1.23), NWBO: 1.72 (+0.01), GLD: 120.54 (-0.19), BBY: 33.57 (+0.05), SHLD: 18.05 (-0.04), PDLI: 3.38 (-0.04)
PDL BioPharma Announces Closing of Transaction Related to LENSAR Debt Investment
PR Newswire - Thu Dec 17, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the closing of the previously announced acquisition of substantially all of LENSAR, Inc.'s (LENSAR) assets by a wholly-owned subsidiary of ALPHAEON Corporation. As part of this acquisition, ALPHAEON's subsidiary entered into an amended and restated credit agreement with PDL and assumed $42 million in loans as part of the borrowings under PDL's prior credit agreement with LENSAR. Also as part of this acquisition, ALPHAEON Corporation issued 1.7 million of its Class A common stock to PDL.
PDLI: 3.38 (-0.04)
PDL BioPharma Completes Regular Quarterly Dividend Payment
PR Newswire - Mon Dec 14, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 11, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 4, 2015, the record date.
PDLI: 3.38 (-0.04)
PDL BioPharma Receives $133.7 Million in Cash Payments
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 3:20PM CST
PDL (PDLI) announced that it received cash payments worth $133.7 million from Nov 1, 2015 through Dec 1, 2015.
BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), PDLI: 3.38 (-0.04)
PDL BioPharma raises USD133.7m in cash payments from income generating assets
M2 - Thu Dec 03, 5:30AM CST
Monoclonal antibodies company PDL BioPharma (PDL) (NasdaqGS DLI) said on Wednesday that it has received USD133.7m in notable cash payments from 1 November 2015 through 1 December 2015.
PDLI: 3.38 (-0.04)
PDL BioPharma Discloses Recent Notable Payments From Income Generating Assets
PR Newswire - Wed Dec 02, 8:01AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today acknowledges receipt of $133.7 million in notable cash payments from November 1, 2015 through December 1, 2015. PDL does not typically report individual payments such as these, but given the interest relating to some of these payments, the company decided to disclose them.
PDLI: 3.38 (-0.04)
3 Dividend Stocks That Retirees Should Avoid
Dan Caplinger, The Motley Fool - Motley Fool - Fri Nov 27, 7:40AM CST
BP Prudhoe Bay production coming down the Alaska Pipeline funds the royalty trust's distributions. Image source: Flickr user Dan. Retirees need investment income, and dividend stocks are a great source of cash in a low-interest-rate environment....
BPT: 29.58 (+1.29), WIN: 7.88 (-0.06), PDLI: 3.38 (-0.04)
Healthcare's Greatest Dividend Stocks
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Tue Nov 24, 7:38AM CST
Ever wonder why certain healthcare stocks are yielding such high dividends? On this Industry Focus , Motley Fool analyst Kristine Harjes and contributor Todd Campbell break it down in terms of what makes a good high-dividend stock, how to do the...
RDUS: 31.80 (+1.06), GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14), GSK: 39.14 (-0.04), PDLI: 3.38 (-0.04)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 21, 4:35PM CST
FIT: 12.86 (+0.39), MDR: 3.88 (+0.03), MIC: 63.98 (+1.47), SREV: 4.32 (+0.01), VECO: 18.96 (+0.27), HURN: 59.54 (+0.67), MHLD: 12.27 (-0.20), OKE: 26.36 (-0.24), SHO: 13.65 (+0.06), MRC: 13.74 (+0.34), ELGX: 9.20 (+0.36), ACC: 43.73 (-0.59), MSI: 70.95 (-0.30), PSIX: 10.97 (-0.03), ONDK: 8.00 (+0.31), VVC: 46.99 (+1.01), THC: 27.06 (-1.03), HLX: 4.55 (-0.17), ESRT: 16.21 (-0.07), PEB: 28.41 (-0.43), SGY: 2.56 (+0.10), ROG: 56.07 (+0.32), OKS: 30.79 (-0.36), CRZO: 26.44 (+0.89), SPN: 12.74 (-0.18), QTS: 45.19 (-0.41), TXRH: 42.82 (+0.59), QUAD: 12.79 (-0.11), IVR: 12.24 (+0.07), NDSN: 74.93 (+0.85), CJES: 1.73 (+0.10), RAIL: 16.24 (-0.10), DEPO: 15.44 (-0.09), PDLI: 3.38 (-0.04), DDS: 84.11 (-0.43), CHGG: 4.40 (-0.07), CHMT: 25.35 (+0.36), TMH: 45.43 (+0.24), LNT: 69.36 (+0.68), MMSI: 19.21 (+0.08), IPHS: 29.62 (+0.92), NLS: 18.25 (+1.36)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 9.04 (+0.22), XNCR: 11.54 (-0.23), PDLI: 3.38 (-0.04)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.71 (-0.01), CLVS: 21.58 (+0.10), RLYP: 13.87 (+0.04), PDLI: 3.38 (-0.04)
PDL BioPharma, Inc. Shares Just Fell Off a Cliff -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 02, 3:30PM CST
What: Shares of PDL BioPharma , a biotech company that focuses on purchasing and developing royalty-based patented assets, sank as much as 13% after the company outlined its new dividend policy. So what: According to PDL BioPharma's press...
PDLI: 3.38 (-0.04)
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
PDLI: 3.38 (-0.04)
PDL BioPharma Announces 2016 First Quarter Dividend
PR Newswire - Mon Feb 01, 3:02PM CST
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the first quarter of 2016. The dividend will be paid on March 11, 2016 to all stockholders who own shares of PDL on March 4, 2016, the record date for the first quarter dividend payment.
PDLI: 3.38 (-0.04)
3 High-Risk Dividend Stocks I'd Avoid
Andrés Cardenal, Tyler Crowe, and George Budwell, The Motley Fool - Motley Fool - Sat Jan 30, 8:20AM CST
Most investors love dividend stocks, and for good reasons. Statistical studies have proven time and again that investing in companies with strong dividends can be a powerful strategy to achieve superior returns from your portfolio over the long...
PM: 94.49 (+1.23), WMB: 19.15 (+1.06), ETE: 8.33 (+0.43), MO: 62.98 (+0.75), WPZ: 22.01 (-1.13), PDLI: 3.38 (-0.04)
Stock to Watch: PDL BioPharma Down 5.4% (PDLI)
Comtex SmarTrend(R) - Mon Jan 11, 12:48PM CST
PDL BioPharma (NASDAQ
DLI) is one of today's worst performing low-priced stocks, down 5.4% to $3.09 on 1.0x average daily volume. Thus far today, PDL BioPharma has traded 2.4 million shares, vs. average volume of 2.4 million shares per day. The stock has underperformed the Dow (-5.4% to the Dow's -0.4%) and underperformed the S&P 500 (-5.4% to the S&P's -0.8%) during today's trading. PDLI: 3.38 (-0.04)
2 Cheap Stocks Not Worth Their (Incredibly Low) Price
Motley Fool Staff - Motley Fool - Tue Jan 05, 2:43PM CST
If you're thinking of investing in stocks under $5, even in mid- and large-cap companies, make sure you're getting a deal instead of low-value paper. As you might expect, a lot of cheap shares are cheap for a reason. In this clip of Industry...
MNKD: 1.17 (+0.07), PDLI: 3.38 (-0.04)
What Makes a Stock "Cheap"?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sat Jan 02, 10:19AM CST
If you're looking to stuff your portfolio with a few little cheap stocks this season, make sure you know how to choose between undervalued steals and junk about to crash and leave you with nothing. On this episode of Healthcare Industry Focus ,...
GILD: 87.21 (-0.62), PFE: 29.71 (-0.18), MYL: 44.78 (-0.95), MNKD: 1.17 (+0.07), PDLI: 3.38 (-0.04)
The Worst 3 Biotech Stocks for 2016
Brian Feroldi, The Motley Fool - Motley Fool - Wed Dec 30, 9:23AM CST
Image by Tax Credits via Flickr Creative Commons. Biotech investing isn't for the faint of heart. It takes more than a decade of research and development efforts costing an average of $2.6 billion to bring just a single drug to market. Even then,...
MNKD: 1.17 (+0.07), ARNA: 1.51 (-0.05), PDLI: 3.38 (-0.04)
5 Stocks We're Staying Away From in 2016
Brian Feroldi, Selena Maranjian, Sean Williams, Brian Stoffel, and Jason Hall, The Motley Fool - Motley Fool - Sun Dec 20, 7:11PM CST
Image by PeteLinforth via Pixabay. Investing in the stock market is one of the best wealth-building tools available to individual investors, as the returns provided from the market's best growth companies can be jaw dropping . Still, finding those...
PM: 94.49 (+1.23), NWBO: 1.72 (+0.01), GLD: 120.54 (-0.19), BBY: 33.57 (+0.05), SHLD: 18.05 (-0.04), PDLI: 3.38 (-0.04)
PDL BioPharma Announces Closing of Transaction Related to LENSAR Debt Investment
PR Newswire - Thu Dec 17, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the closing of the previously announced acquisition of substantially all of LENSAR, Inc.'s (LENSAR) assets by a wholly-owned subsidiary of ALPHAEON Corporation. As part of this acquisition, ALPHAEON's subsidiary entered into an amended and restated credit agreement with PDL and assumed $42 million in loans as part of the borrowings under PDL's prior credit agreement with LENSAR. Also as part of this acquisition, ALPHAEON Corporation issued 1.7 million of its Class A common stock to PDL.
PDLI: 3.38 (-0.04)
PDL BioPharma Completes Regular Quarterly Dividend Payment
PR Newswire - Mon Dec 14, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 11, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 4, 2015, the record date.
PDLI: 3.38 (-0.04)
PDL BioPharma Receives $133.7 Million in Cash Payments
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 3:20PM CST
PDL (PDLI) announced that it received cash payments worth $133.7 million from Nov 1, 2015 through Dec 1, 2015.
BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), PDLI: 3.38 (-0.04)
PDL BioPharma raises USD133.7m in cash payments from income generating assets
M2 - Thu Dec 03, 5:30AM CST
Monoclonal antibodies company PDL BioPharma (PDL) (NasdaqGS
DLI) said on Wednesday that it has received USD133.7m in notable cash payments from 1 November 2015 through 1 December 2015. PDLI: 3.38 (-0.04)
PDL BioPharma Discloses Recent Notable Payments From Income Generating Assets
PR Newswire - Wed Dec 02, 8:01AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today acknowledges receipt of $133.7 million in notable cash payments from November 1, 2015 through December 1, 2015. PDL does not typically report individual payments such as these, but given the interest relating to some of these payments, the company decided to disclose them.
PDLI: 3.38 (-0.04)
3 Dividend Stocks That Retirees Should Avoid
Dan Caplinger, The Motley Fool - Motley Fool - Fri Nov 27, 7:40AM CST
BP Prudhoe Bay production coming down the Alaska Pipeline funds the royalty trust's distributions. Image source: Flickr user Dan. Retirees need investment income, and dividend stocks are a great source of cash in a low-interest-rate environment....
BPT: 29.58 (+1.29), WIN: 7.88 (-0.06), PDLI: 3.38 (-0.04)
Healthcare's Greatest Dividend Stocks
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Tue Nov 24, 7:38AM CST
Ever wonder why certain healthcare stocks are yielding such high dividends? On this Industry Focus , Motley Fool analyst Kristine Harjes and contributor Todd Campbell break it down in terms of what makes a good high-dividend stock, how to do the...
RDUS: 31.80 (+1.06), GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14), GSK: 39.14 (-0.04), PDLI: 3.38 (-0.04)
